TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04644016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan per PK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan per PK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Graft
Description: The CB graft will be infused on day 0 per standard practice

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood Graft
Description: The CB graft will be infused on day 0 per standard practice
Study: NCT03698136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation of denervated muscles
Description: The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
Study: NCT04386408

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of plant extracts (BSL_EP027)
Description: Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
Study: NCT02462434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early palliative care team consultation
Description: The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
Study: NCT00006034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Description: Given intradermally and IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02960776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Description: Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
Study: NCT00877994

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurture Support Group Therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurture Support Group Therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
Study: NCT03361735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Intramuscular or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Subcutaneous injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous injection
Study: NCT03337503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC and CDB in a 1 to 1 ratio
Description: capsule containing cannabis oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: THC and CBD in a 1 to 2 ratio
Description: capsule containing cannabis oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High CBD with trace THC oil
Description: capsule containing cannabis oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: carrier oil capsule
Study: NCT03869034

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HAIC+PD1
Description: Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
Study: NCT00877994

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
Study: NCT04544852

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current practice
Description: Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted intervention programme
Description: The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
Study: NCT01109576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSL Workshop
Description: A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
Study: NCT04381676

Intervention type: OTHER
Intervention: Flipped Classroom Approach
Description: In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
Study: NCT01188226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture teeth
Description: Denture teeth made of nano hybrid composite material
Study: NCT04643743

Intervention type: DEVICE
Intervention: Endarterectomy
Description: Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
Study: NCT00323089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microcoil insertion and excision
Description: The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
Study: NCT02583074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-stimulation
Description: After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
Study: NCT01182870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choleclaciferol
Description: 800-6000 IU cholecalciferol per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: choleclaciferol
Description: 800-6000 IU cholecalciferol per day
Study: NCT01162655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for Insomnia (CBT)
Description: 6-week course of CBT delivered either using internet or telehealth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for Insomnia (CBT)
Description: 6-week course of CBT delivered either using internet or telehealth
Study: NCT03410667

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase One: Exploration
Description: Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase Two: Creation
Description: Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phase Three: Reflection
Description: This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim 3
Description: This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
Study: NCT03936062

Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the exposure

Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT00575978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Study: NCT03618095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS Edge Valve System
Description: TAVR with the LOTUS Edge Valve System
Study: NCT03765567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
Study: NCT02789631

Intervention type: OTHER
Intervention: assessment

Intervention type: OTHER
Intervention: assessment
Study: NCT00392080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-023,423
Description: 75 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Description: naproxen
Study: NCT02298023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogenic adipose stem cell injection
Description: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue/normal saline injection
Description: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline injection
Description: Total 1cc of normal saline injection and range of motion exercise
Study: NCT03623555

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback.

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback.

Intervention type: BIOLOGICAL
Intervention: Salivary cortisol
Description: Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST

Intervention type: BIOLOGICAL
Intervention: Salivary cortisol
Description: Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
Study: NCT02628938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak extract mouth wash
Description: 50% Miswak extract mouth wash (5ml) twice a day for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak stick
Description: Miswak stick twice a day for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexidine gluconate
Description: 5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
Study: NCT01398553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring
Description: 30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
Study: NCT01578421

Intervention type: DEVICE
Group type: OTHER
Intervention: 4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)
Description: 4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements

Intervention type: DEVICE
Group type: OTHER
Intervention: 4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)
Description: 4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements

Intervention type: DEVICE
Group type: OTHER
Intervention: 4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)
Description: 4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
Study: NCT03855228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nasal spray
Description: Daily dose of placebo administered as a nasal spray for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Daily dose of placebo administered as a nasal spray for 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Daily dose of placebo administered as an oral tablet for 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Daily dose of placebo administered as an oral tablet for 15 days.
Study: NCT03042325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT00722800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drospirenone and ethinyl estradiol (YAZ)
Description: 1 tablet daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 24 weeks
Study: NCT03101787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Description: In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes.